University Hospital Tübingen

What University Hospital Tübingen does

University Hospital Tübingen (Universitätsklinikum Tübingen) is a public university hospital and medical faculty affiliated with Eberhard Karls Universität Tübingen, located in Tübingen, Baden-Württemberg, Germany. The institution operates as a Maximalversorgung (maximum care) hospital and district hospital, delivering comprehensive inpatient and outpatient care across all medical specialties to approximately 513,819 patients annually. It employs 11,613 staff, including more than 135 professors, and educates 4,979 medical students through its integrated Medical Faculty. The hospital is organized around three pillars: clinical care (Krankenversorgung), research (Forschung), and teaching (Lehre), with research excellence concentrated in three Excellence Clusters — CMFI (Controlling Microbes to Fight Infections), iFIT (Image-guided and Functionally Instructed Tumor Therapies), and Machine Learning for Science — and a nationwide-unique Clinical Cooperation Unit for Translational Immunology (KKE Translationale Immunologie).

The hospital's revenue model combines reimbursement from the German public health insurance system (GKV statutory and PKV private insurance) for clinical services with third-party research funding from the German Research Foundation (DFG), European Union, Helmholtz Association, and other public research funders. As a non-profit state institution, it does not operate on commercial revenue mechanics; rather, it allocates an operating budget across patient care, translational research, and educational programs. Its go-to-market is direct-to-consumer via clinical care delivery (inpatient, outpatient, emergency), supplemented by a regional physician referral network and an international patient services channel. Proprietary research assets include the bispecific PSMAxCD3 antibody CC-1 (co-developed with DKFZ for prostate cancer immunotherapy), CRISPR/Cas9 NFIL3 gene editing work for CAR T-cell therapy, and ATF6α research in hepatocellular carcinoma, alongside structured clinical trial coordination through the Center for Clinical Studies Tübingen (ZKS Tübingen). Recent strategic partnerships with Columbia University, Elicera Therapeutics, Helmholtz Munich, and the German Center for Diabetes Research reflect ongoing expansion of the translational research pipeline.

Name

University Hospital Tübingen

Legal name

Universitätsklinikum und Medizinische Fakultät der Eberhard Karls Universität Tübingen

Website

https://medizin.uni-tuebingen.de

Company type

Private

Founded year

1805

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

University Hospital Tübingen is a German public university hospital and medical faculty affiliated with Eberhard Karls Universität Tübingen, delivering maximum care clinical services to over 513,000 patients annually while conducting biomedical research across three Excellence Clusters and educating nearly 5,000 medical students.

Ownership category

akta.pro rank

Product category

Academic Medical Center

NAICS

General Medical and Surgical Hospitals (62211), Hospitals (622)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Community & Regional General Hospitals (HLAFAAAB)

Keywords

• University hospital services
• Academic medical center
• Clinical research programs
• Medical education
• Translational medicine

Headquarters

HQ city

Tübingen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Care Revenue: Reimbursement through German public health insurance system (GKV/PKV) for medical treatment services provided to approximately 513,819 patients annually.
2. Research Funding and Grants: Third-party funding from German Research Foundation (DFG), European Union, Helmholtz Association, and other research funders supporting excellence clusters, Sonderforschungsbereiche (SFB), and clinical research programs.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

University Hospital Tübingen (Universitätsklinikum Tübingen) is a German maximum care hospital (Krankenhaus der Maximalversorgung) and the university hospital of Eberhard Karls Universität Tübingen. It delivers comprehensive inpatient and outpatient medical care across all specialties to approximately 513,819 patients annually, while simultaneously conducting biomedical and clinical research and providing academic medical training through its affiliated Medical Faculty.

Product overview

University Hospital Tübingen (Universitätsklinikum Tübingen) operates as a German university hospital affiliated with Eberhard Karls University Tübingen, organized around three core pillars: medical care (Krankenversorgung), research (Forschung), and education (Lehre). The hospital provides comprehensive healthcare services across all medical specialties while simultaneously conducting medical research through numerous institutes and clinical research programs. Its Medical Faculty offers structured academic career programs including the Talent Academy for young scientists with tracks for Clinician Scientists, Biomedical Scientists, Data Scientists, and Medical Educator Scientists, as well as a PhD Program in Experimental Medicine. Research activities span diverse areas including immunology, oncology, infection medicine, neurosciences, and medical AI, with notable programs such as the bispecific antibody CC-1 immunotherapy trial and various excellence clusters (CMFI, iFIT, Machine Learning).

Differentiator

Problem solved

Functional benefit

Brands

• Talent Academy: Platform for young scientists providing customized qualification programs for career development in science tracks including Clinician Scientist, Biomedical Scientist, Data Scientist, and Medical Educator Scientist.
• TÜ-SEED
• TIME - Tübingen Institute for Medical Education
• PULS Online

Products and services

• Medical Care Services (Krankenversorgung)
• Medical Research Programs (Forschung)
• Medical Education (Lehre)
• Clinical Trials Coordination
• Bispecific Antibody CC-1 Immunotherapy Study
• PhD Program in Experimental Medicine
• Talent Academy Qualification Programs
• Clinician Scientist Programs

Quantifiable outcome

• 513,819 patients treated annually
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core.

• Columbia UniversitycoreStrategic or Co-development Partner · 2 June 2026Joint research collaboration with Columbia University researchers to identify NFIL3 protein's role in CAR T-cell exhaustion. Using CRISPR/Cas9 gene editing to disable NFIL3 to improve CAR T-cell therapy effectiveness for cancer treatment, particularly solid tumors.
• Elicera Therapeutics ABcoreStrategic or Co-development Partner · 13 February 2026Clinical collaboration using University Hospital Tübingen's iTANK platform for CAR T-cell therapy in Elicera's CARMA Phase I/IIa study. Four of six patients achieved complete metabolic response with iTANK-armed CAR T-cell therapy.
• German Cancer Research Center (DKFZ)coreStrategic or Co-development Partner · 4 February 2026Research collaboration with DKFZ and Sanford Burnham Prebys identifying ATF6α as tumor driver for hepatocellular carcinoma. Study demonstrated ATF6α paradoxically makes tumors highly responsive to immune checkpoint blockade therapy.
• Sanford Burnham Prebys Medical Discovery InstitutecoreStrategic or Co-development Partner · 4 February 2026Collaborative research on liver cancer and immunotherapy response, identifying ATF6α's role in tumor metabolism and immune suppression.
• Helmholtz MunichcoreStrategic or Co-development Partner · 7 October 2025Joint research with Helmholtz Munich and German Center for Diabetes Research on diabetes prevention through lifestyle changes without weight loss. Study tracked over 1,100 participants showing 71% reduction in diabetes development through blood sugar normalization.
• German Center for Diabetes Research (DZD)coreStrategic or Co-development Partner · 7 October 2025Collaboration on German Prediabetes Lifestyle Intervention Study (PLIS) demonstrating that prediabetes can be reversed without weight loss by focusing on fat distribution and blood sugar control.
• DKTK (German Consortium for Translational Cancer Research) - Multiple SitescoreStrategic or Co-development Partner · 1 November 2021Phase I clinical trial of bispecific antibody CC-1 conducted at multiple DKTK sites including Berlin, Freiburg, Mainz, Frankfurt, and Heidelberg, in addition to University Hospital Tübingen as the coordinating center.
• German Cancer Research Center (DKFZ) - Joint Antibody DevelopmentcoreStrategic or Co-development Partner · 1 November 2021Co-development of bispecific PSMAxCD3 antibody CC-1 with DKFZ for prostate cancer immunotherapy. Joint intellectual property and clinical development collaboration.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Universitätsklinikum Essen (Universitätsmedizin Essen): University hospital of the University of Duisburg-Essen with a strong oncology and infectious disease research profile, comparable as a full Maximalversorger in the Ruhr region.
• Universitätsklinikum Erlangen: University hospital of Friedrich-Alexander-Universität Erlangen-Nürnberg, comparable as a Maximalversorger in Bavaria with full-spectrum specialty care and active research programs.
• Universitätsklinikum Hamburg-Eppendorf (UKE): Hamburg's university hospital operating as a Maximalversorger with a strong research and education profile. Comparable size, structure, and full-spectrum specialty care model.
• Universitätsklinikum Heidelberg: One of Germany's leading university hospitals and a partner of the National Center for Tumor Diseases (NCT). Comparable as a Maximalversorger with strong translational oncology, DKFZ collaboration, and excellence-cluster presence.
• Universitätsklinikum Freiburg: University hospital of the University of Freiburg with similar focus on oncology, immunology, and translational research, and comparable scale in southern Germany.
• Charité – Universitätsmedizin Berlin: Germany's largest university hospital, jointly operated by Freie Universität Berlin and Humboldt-Universität. Directly comparable as a Maximalversorger academic medical center combining clinical care, research, and teaching with similar excellence-cluster funding and specialty depth.
• Universitätsklinikum Bonn: University hospital of the University of Bonn with comparable scale, comprehensive specialty offering, and active participation in German translational research networks.
• Universitätsklinikum Frankfurt (Universitätsmedizin Frankfurt): Goethe University Frankfurt's university hospital, comparable as a Maximalversorger with strong research profile and DKTK oncology trial participation.
• Universitätsklinikum Köln: University hospital of the University of Cologne with full Maximalversorger function and similar translational research and teaching profile.
• LMU Klinikum (Ludwig-Maximilians-Universität München): University hospital of LMU Munich with comparable scale (~11,000+ employees), full-spectrum clinical services, and a high research output in immunology and oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/uktuebingen
• YouTubeyoutube.com/@uniklinikumtuebingen
• LinkedInlinkedin.com/company/universitatsklinikum-tubingen
• Instagraminstagram.com/uniklinikumtuebingen

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University Hospital Tübingen